Sanofi Reports meta-analysis Data for Venetoclax in Urothelial carcinoma

Sanofi today announced meta-analysis results for Venetoclax in patients with Urothelial carcinoma. The study demonstrated that Venetoclax demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Urothelial carcinoma and support the continued development of Venetoclax in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Venetoclax was consistent with previous observations, with no new safety signals identified.